Eight Mandate Exits in One Quarter: Rebalancing the Dual-Mandate Book
The Balanced Dividend Strategy is the portfolio for investors who refuse to choose between today's paycheck and tomorrow's raise. Every holding must clear a dual screen: at least 1.5% forward yield and at least 5% five-year dividend growth. The book targets 3.0% blended yield with 6.5% income growth — the middle path between the Income Strategy's rigid yield floor and the Income Growth Strategy's compounding flywheel.
Q3 was the heaviest rotation since inception: 8 full exits, one cap trim, and a full replacement slate executed across July 1 and July 3. This wasn't a nuclear overhaul of 14 names — the SQL audit scoped it to Tier 1 mandate failures and dual-mandate breaches. Post-trade, the book passes every sector band and both blended floors: 2.8% forward yield and 9.1% weighted dividend CAGR. Every number below comes from the same data file as the condensed report — read the full article at Dividend-Wealth.com.
Just want the numbers? Read the condensed rebalance report
Every trade, weight, and sector exhibit — marked to market from the live position file.
Accountability first
Flat on price, trailing DGRO
Pre-trade, this book was up just +0.4% price-only since January — $95,985 on a $95,563 founding value. DGRO returned +11.5% over the same window, a gap of roughly 11 percentage points. The dual mandate book is designed to lag pure growth in risk-on halves and lag pure income in risk-off halves; a flat first half against a rising benchmark is exactly the kind of quarter that tempts you to trade on feelings. The rulebook traded on screens instead.
Pre-trade price return was nearly flat (+0.4%) while DGRO ran +11.5% — a 11pp gap. The rebalance was about mandate hygiene, not chasing the benchmark tape.
The book passed January floors (yield 2.70%, growth 8.1%) but several individual names failed the dual screen — that's what triggered the rotation.
July scope
July scope — mandate exits only (Q3 2026)
Blended book passed January floors pre-trade (yield 2.70%, growth 8.1%). July rotated C-verdict names and dual-mandate failures (TXN, AVGO, EMR, BLK, PG), trimmed JPM, and exited cyclical/payout flags (HD, MCD, ABBV). Payout-only watchlist names not held through July were already sold or never re-added. Post-trade book passes all sector bands and blended audit (yield 2.78%, growth 9.1%).
The trades
8 exits, 1 trim, 10 buys
The mandate exits cluster into two buckets. C-verdict failures — TXN, EMR, BLK, PG — failed payout or growth deceleration on live SQL. Dual-mandate failures — AVGO at 0.70% yield, below the 1.5% floor — and cyclical/payout flags in HD, MCD, and ABBV. JPM was the lone trim: 6.26% weight, two shares off to respect the 6% cap.
| Ticker | Why | Shares | Est. $ |
|---|---|---|---|
| TXN | C — FCF 192%, 3y CAGR 4.9% | −26 | −$7,759 |
| AVGO | Dual-mandate — yield 0.70% < 1.5% | −16 | −$5,909 |
| EMR | C — 5y CAGR 1.3%, 3y decel | −38 | −$5,302 |
| BLK | C — FCF 94%, 3y decel | −5 | −$4,902 |
| PG | C — FCF 70%, 3y decel | −33 | −$4,865 |
| JPM | 6.26% · over 6% cap — trim 2 sh | −2 | −$668 |
| ABBV | Payout 65.4% + sector trim | −23 | −$5,774 |
| MCD | Consumer Cyclical trim + payout flag | −15 | −$4,041 |
| HD | Consumer Cyclical trim + payout flag | −15 | −$5,263 |
| WM | Replaces EMR | +24 | +$5,378 |
| TROW | Replaces BLK (53 sh total position) | +53 | +$6,154 |
| KO | Replaces PG | +62 | +$5,040 |
| AFL | Financials depth | +46 | +$5,451 |
| ROL | Consumer Cyclical compounder (104 sh total) | +104 | +$4,440 |
| ADM | Consumer Defensive / agriculture | +90 | +$6,911 |
| CSCO | Tech sleeve — 80 sh @ $117 (Jul 2026) | +80 | +$9,361 |
| ELV | Healthcare — managed care | +10 | +$4,162 |
| ZTS | Healthcare — animal health | +60 | +$4,347 |
| ACN | ADD band — top up 13 sh | +13 | +$1,786 |
| CMCSA | ADD band — top up 35 sh | +35 | +$833 |
Sells raised $44,484; buys deployed $53,861. The July 3 pass sized CSCO to 80 shares (~9% weight at entry, January trim watch), TROW to 53 shares total, and added ROL, ADM, ELV, and ZTS to fill sector gaps the first session left open.
New positions
Dual-mandate replacements
Every replacement had to pass both screens on execution day — enough yield for today's paycheck, enough growth for tomorrow's raise.
2.8% · 20.1% CAGR
Animal health — growth + yield.
TROW replaces BLK with a name that actually pays — 4.4% yield, 38-year streak, inside the payout ceiling. KO swaps in for PG with a cleaner growth profile. CSCO rebuilds the Technology sleeve after TXN andAVGO left; it's the one position already flagged over the 6% cap at 8.4% — documented now, trimmed in January if it still breaches. ROL and ADM weren't in the headline replacement cards but they're real positions — pest control and agriculture staples that pass both screens.
Post-trade
The book after July 3
Post-trade audit: $107,022 market value, $2,970 forward income, blended yield 2.8% (target 3.0%), blended growth 9.1%. Twenty names, every sector sleeve within ±3pp.
Every sleeve within ±3pp of target after the July 3 sector-correction pass. Healthcare runs +2.6pp — acceptable until January trim review.
Income picture
What exited and what stayed
Pre-trade yield was 2.7%; the top five payers carried 35% of forward income. CMCSA was the #1 payer — it stayed and was topped up. The exits removed the dual-mandate failures and C-verdict names that were dragging the growth side without paying enough yield to justify the slot.
Looking ahead
January watchlist
Q3 is complete. Four names are already flagged for January: CSCO and ADM over the 6% cap; MRK, PEP, CVX, NEE, and JNJ on payout soft-fails — hold unless a second filing confirms deterioration. The Annual Balance Audit in January will re-check that blended yield stays above 2.5% and blended growth above 5.0%. If you want the condensed ledger, read the condensed rebalance report.